Yang H, Zhang Q, He J, Lu W
J Thorac Dis. 2012; 2(1):52-6.
PMID: 22263018
PMC: 3256429.
Leontieva O, Preobrazhenskaya M, Bernacki R
Invest New Drugs. 2002; 20(1):35-48.
PMID: 12003193
DOI: 10.1023/a:1014415205955.
Alexanian A, Arutyunian N
Invest New Drugs. 2000; 17(2):105-10.
PMID: 10638481
DOI: 10.1023/a:1006397014409.
Sakaguchi Y, Maehara Y, Inutsuka S, Takahashi I, Yoshida M, Emi Y
Cancer Chemother Pharmacol. 1994; 33(5):371-7.
PMID: 8306410
DOI: 10.1007/BF00686265.
Ishida H, Okabe M, Gomi K, Horiuchi R, Mikami K, Naito M
Jpn J Cancer Res. 1994; 85(5):542-9.
PMID: 8014112
PMC: 5919497.
DOI: 10.1111/j.1349-7006.1994.tb02393.x.
Reversal of multidrug resistance by a novel quinoline derivative, MS-209.
Sato W, Fukazawa N, Nakanishi O, Baba M, Suzuki T, Yano O
Cancer Chemother Pharmacol. 1995; 35(4):271-7.
PMID: 7828268
DOI: 10.1007/BF00689444.
Adriamycin and daunomycin dose-dependent effects upon contractions of isolated rat myocytes.
Lowe M, Smallwood J
Cancer Chemother Pharmacol. 1980; 5(1):61-5.
PMID: 7460195
DOI: 10.1007/BF00578564.
Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells.
Baskin F, Rosenberg R, Dev V
Proc Natl Acad Sci U S A. 1981; 78(6):3654-8.
PMID: 6943568
PMC: 319629.
DOI: 10.1073/pnas.78.6.3654.
Cytofluorescence localization of adriamycin in resistant colon cancer cells.
Chauffert B, Martin F, Caignard A, Jeannin J, Leclerc A
Cancer Chemother Pharmacol. 1984; 13(1):14-8.
PMID: 6733840
DOI: 10.1007/BF00401439.
Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.
Slater L, Murray S, Wetzel M, Wisdom R, DUVALL E
J Clin Invest. 1982; 70(5):1131-4.
PMID: 6182160
PMC: 370327.
DOI: 10.1172/jci110702.
Reversal of natural resistance to bouvardin (NSC 259968) in sarcoma 180 cells in vitro and in vivo by verapamil.
Chitnis M, Menon R, Basrur V, Adwankar M, Satyamoorthy K
J Cancer Res Clin Oncol. 1985; 110(3):221-4.
PMID: 4077920
DOI: 10.1007/BF00399277.
Comparative cytotoxicities of various morpholinyl anthracyclines.
Streeter D, Taylor D, ACTON E, Peters J
Cancer Chemother Pharmacol. 1985; 14(2):160-4.
PMID: 3971481
DOI: 10.1007/BF00434357.
Comparison of the cellular pharmacology of doxorubicin in resistant and sensitive models of pancreatic cancer.
Chang B, Gregory J
Cancer Chemother Pharmacol. 1985; 14(2):132-4.
PMID: 3971476
DOI: 10.1007/BF00434351.
Uptake and metabolism of daunorubicin by human myelocytic cells.
Vasanthakumar G, Ahmed N
Cancer Chemother Pharmacol. 1985; 15(1):35-9.
PMID: 3891121
DOI: 10.1007/BF00257291.
Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry.
Ganapathi R, Gulick P, Miller R, Grabowski D, Turinic R, Valeunzuela R
Invest New Drugs. 1985; 3(3):273-7.
PMID: 3864764
DOI: 10.1007/BF00179431.
Doxorubicin binds in a cooperative manner to myocardial cells. Two binding sites.
Wassermann K, Steiness E
Cancer Chemother Pharmacol. 1986; 17(3):241-6.
PMID: 3742710
DOI: 10.1007/BF00256692.
9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures.
Scott C, Westmacott D, Broadhurst M, Thomas G, Hall M
Br J Cancer. 1986; 53(5):595-600.
PMID: 3718817
PMC: 2001372.
DOI: 10.1038/bjc.1986.101.
Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells.
Ganapathi R, Yen A, Grabowski D, Schmidt H, Turinic R, Valenzuela R
Br J Cancer. 1986; 53(4):561-6.
PMID: 3707847
PMC: 2001449.
DOI: 10.1038/bjc.1986.88.
Potentiation of vincristine by vitamin A against drug-resistant mouse leukaemia cells.
Nogae I, Kikuchi J, Yamaguchi T, Nakagawa M, Shiraishi N, Kuwano M
Br J Cancer. 1987; 56(3):267-72.
PMID: 3663474
PMC: 2002191.
DOI: 10.1038/bjc.1987.188.
Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells.
Vasanthakumar G, Ahmed N
Cancer Chemother Pharmacol. 1986; 18(2):105-10.
PMID: 3539383
DOI: 10.1007/BF00262277.
